These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 11581246)

  • 1. Activity of linezolid against levofloxacin-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in Hong Kong.
    Ho PL; Ng TK; Yung RW; Que TL; Yip EK; Tse CW; Yuen KY
    J Antimicrob Chemother; 2001 Oct; 48(4):590-2. PubMed ID: 11581246
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
    Patel R; Rouse MS; Piper KE; Steckelberg JM
    Diagn Microbiol Infect Dis; 1999 Jun; 34(2):119-22. PubMed ID: 10354862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009.
    Dowzicky MJ; Chmelařová E
    Int J Antimicrob Agents; 2011 Jun; 37(6):562-6. PubMed ID: 21497066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility testing with linezolid by different methods, in relation to published 'general breakpoints'.
    Livermore DM; Mushtaq S; Warner M
    J Antimicrob Chemother; 2001 Sep; 48(3):452-4. PubMed ID: 11533020
    [No Abstract]   [Full Text] [Related]  

  • 5. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
    Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
    Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linezolid, levofloxacin, and vancomycin against vancomycin-tolerant and fluoroquinolone-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model.
    Cha R; Akins RL; Rybak MJ
    Pharmacotherapy; 2003 Dec; 23(12):1531-7. PubMed ID: 14695032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study.
    Ross JE; Fritsche TR; Sader HS; Jones RN
    Int J Antimicrob Agents; 2007 Mar; 29(3):295-301. PubMed ID: 17239570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
    Presterl E; Mueller-Uri P; Grisold A; Georgopoulos A; Graninger W
    Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):486-9. PubMed ID: 11561805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activity of linezolid and five other antimicrobials against nosocomial isolates of methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium.
    Metallidis S; Chatzidimitriou M; Nikolaidis P; Tsona A; Bisiklis A; Kollaras P; Tsiakiri E; Koumentaki E; Alexiou-Daniel S
    J Chemother; 2003 Oct; 15(5):442-8. PubMed ID: 14603881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-antibiotic growth suppression of linezolid against Gram-positive bacteria.
    Munckhof WJ; Giles C; Turnidge JD
    J Antimicrob Chemother; 2001 Jun; 47(6):879-83. PubMed ID: 11389123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.
    Sweeney MT; Zurenko GE
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1902-6. PubMed ID: 12760865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
    Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
    J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011.
    Flamm RK; Mendes RE; Ross JE; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2013 Jun; 76(2):206-13. PubMed ID: 23478031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States.
    Mendes RE; Flamm RK; Hogan PA; Ross JE; Jones RN
    Antimicrob Agents Chemother; 2014; 58(2):1243-7. PubMed ID: 24323470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
    Patel R; Rouse MS; Piper KE; Steckelberg JM
    Diagn Microbiol Infect Dis; 2000 Nov; 38(3):177-9. PubMed ID: 11109018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
    Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains.
    Shaw KJ; Poppe S; Schaadt R; Brown-Driver V; Finn J; Pillar CM; Shinabarger D; Zurenko G
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4442-7. PubMed ID: 18838596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of linezolid in antimicrobial therapy].
    Carmona PM; Romá E; Monte E; García J; Gobernado M
    Enferm Infecc Microbiol Clin; 2003 Jan; 21(1):30-41. PubMed ID: 12550042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro activity of penicillin G, levofloxacin, moxifloxacin, telithromycin, pristinamycin, quinupristin-dalfopristin and linezolid against ofloxacin-intermediate and -resistant Streptococcus pneumoniae.
    Frédénucci I; Chomarat M; Bercion R; Carricajo A; Celard M; Croizé J; Delubac F; Fèvre D; Fuhrmann C; Helfre M; Letouzey MN; Lelièvre H; Mandjee A; Marthelet P; Meley R; Perrier-Gros-Claude JD; Ros A; Roure C; Smati S; Thierry J; Tous J
    Clin Microbiol Infect; 2002 Oct; 8(10):680-3. PubMed ID: 12390289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
    Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
    Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.